Simple and Objective Prediction of Survival in Patients with Lung Cancer: Staging the Host Systemic Inflammatory Response

Table 3

The relationship between the mGPS and clinicopathological characteristics in patients with lung cancer.

Demographic	mGPS			𝑃 value (chi-square test)
	0 (𝑛=213)	1 (𝑛=290)	2 (𝑛=218)
Age
<60/60–69/70–79/≥80 years	33/71/89/28	44/87/119/54	34/57/91/49	0.064
Sex
Male/female	115/108	174/130	133/98	0.201
Centre
Aber/Fife/Stob/Inver	98/10/77/38	146/25/66/67	43/16/126/46	<0.001
Deprivation
Most-least (quintile)	68/24/71/39/21	75/47/75/77/30	111/21/70/20/9	<0.001
Smoke (pack years)
NS/<20/20–60/>60	21/24/126/37	11/33/177/69	13/21/128/57	0.014
Performance status
0/1/2/3/4	42/96/60/22/3	26/130/105/40/3	5/51/88/66/21	<0.001
Weight loss (%)
0/<5/5–10/>10	147/24/12/38	146/36/13/109	79/45/33/73	<0.001
FEV1 (%)
<80/61–80/40–60/<40	138/31/45/7	181/48/53/22	130/33/47/17	0.126
Local symptoms
No/yes	36/127	18/222	29/137	0.246
Tumour stage of NSCLC
I/II/IIIa/IIIb/IV	32/11/7/38/38	15/19/20/56/84	7/5/12/36/79	<0.001
Tumour stage of SCLC
Limited/extensive	13/21	10/32	8/18	0.471
Treatment
Radical treatment
Surgery/RT/no active	26/9/38	17/15/43	4/2/18	<0.001
Palliative treatment
Chemo/RT/No active	63/27/49	107/58/55	50/49/75	<0.001
Survival
Alive/dead	34/181	16/274	8/211	0.003
12-month survival % (SE)	46 (4)	16 (2)	14 (3)	<0.001